The Filing Desk

Fresenius Medical Care

FMS · NYSE · Health Care · Financials, fiscal 2016 to 2025

FMS · Last close · November 19, 2026
$20.13

Fresenius Medical Care's revenue rose 1.5% to €19.6 billion in fiscal 2025. Its operating margin was 9.3%, up from 7.2% a year earlier. It paid out €1.0 billion in dividends and buybacks. The diluted share count fell 0.8%.

FRESENIUS MEDICAL CARE AG Latest fiscal year ended December 31, 2025 20-F filed February 24, 2026 · 0001104659-26-019005 Updated
Revenue
€19.6B
1.5%
Operating margin
9.3%
2.1 pts
Net income
€978M
81.9%
Free cash flow
—
 
Return on capital
7.0%
2.4 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

About these figures. Fresenius Medical Care is a foreign company: it files an annual report on Form 20-F, prepared under international accounting standards (IFRS), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model. Its figures are in EUR, as it reports them: they aren't converted to US dollars.

What Fresenius Medical Care does

Fresenius Medical Care provides products and services for people with kidney disease. It describes itself as the world's largest provider by publicly reported revenue. It combines medical device manufacturing with patient care, mainly dialysis, a procedure that cleans the blood when the kidneys fail.

It runs three segments: Care Delivery (its dialysis clinics and related services), Value-Based Care (programs in which it manages the cost and quality of care for groups of patients) and Care Enablement (the products it makes and sells, such as dialysis machines, supplies and pharmaceuticals). It sells products to customers in more than 140 countries and operates 35 production sites in 19 countries.

At the end of 2025 it operated 3,601 dialysis centers in more than 30 countries, serving 291,902 patients, down from the year before after it sold some operations. It had 109,698 employees.

Its biggest risks, as it describes them

  • Changes in government reimbursement, payor mix or healthcare rules that could cut its revenue and profit.
  • Legislative reform of its highly regulated industry that could change how it operates.
  • Rules on its value-based care programs and investments, with legal exposure if found to violate the law.
  • Losing patient referrals from doctors, and competitors with better technology or generic drugs.
  • Product liability and patent claims, and cyber-attacks or data breaches.
From Fresenius Medical Care's annual report on Form 20-F, filed February 24, 2026, in our words; the 20-F has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
EUR billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
EUR billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share fell 1.2% a year and net income 1.7% a year, while buybacks cut the share count by 5%.

Diluted earnings per share
EUR per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
EUR billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
EUR billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1,4821,2741,4041,1801,599
Debt incl. finance leases8,5718,5147,9046,8387,288
Net debt (negative means net cash)7,0897,2406,5015,6585,689
Net debt to EBITDA2.1x2.2x2.2x1.9x1.7x
Debt to equity0.7x0.6x0.6x0.5x0.6x
Interest coverage5.4x4.2x3.2x3.5x4.9x
Current ratio1.1x1.3x1.4x1.4x1.3x
Quick ratio0.8x0.9x1.1x1.0x0.9x
EUR millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
EUR billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
EUR billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
EUR billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score5 of 97 of 97 of 9
Rule of 40———
Altman Z''2.642.752.93
Accruals ratio−6.1%−5.5%−5.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassFail
Current ratio rosePassFailFail
Share count didn't riseFailPassPass
Gross margin roseFailFailPass
Revenue rose relative to assetsFailPassPass
F-score5 of 97 of 97 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Fresenius Medical Care side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Fresenius Medical CareFY251.5%9.3%—7.0%1.7x7
LabcorpFY257.2%9.9%8.6%8.2%2.5x7Compare
DaVitaFY256.5%15.0%9.6%17.6%3.5x6Compare
BrightSpring Health ServicesFY2528.2%2.3%3.1%5.2%5.3x7Compare
Quest DiagnosticsFY2511.8%14.1%12.3%9.5%2.5x6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue16,57017,78416,54717,47717,85917,61919,39819,45419,33619,628
Revenue growth7.2%7.3%−7.0%5.6%2.2%−1.4%10.1%0.3%−0.6%1.5%
Gross profit5,6166,0185,1555,3965,5375,0775,3104,9254,7575,029
Research and development146111114168194221229232184158
Operating income2,4092,3623,0382,2702,3041,8521,5121,3691,3921,827
Net income1,1441,2801,9821,2001,164969673499538978
Diluted EPS (EUR)3.734.166.453.963.963.312.301.701.833.36
Diluted shares (millions)306307306303294293293293293291
Cash flow
Cash from operations1,9322,1922,0622,5674,2332,4902,1672,6292,3862,681
Capital expenditure9309441,0571,125——————
Free cash flow1,0011,2471,0051,442——————
Dividends paid244294325355351392396329349422
Share buybacks058376003660000585
Acquisitions05212502,160215325103015
Stock-based compensation2747112——————
Balance sheet at fiscal year end
Cash and short-term investments7099782,2451,0081,0821,4821,2741,4041,1801,599
Debt incl. finance leases8,1297,4397,3579,0777,8888,5718,5147,9046,8387,288
Total assets25,50424,02526,24232,93531,68934,36735,75433,93033,56731,002
Total liabilities14,45213,19713,34019,70819,35820,38820,30519,10317,79816,720
Shareholders' equity9,9789,82011,75811,95811,21512,69913,99013,62014,57713,310
Margins and ratios
Gross margin33.9%33.8%31.1%30.9%31.0%28.8%27.4%25.3%24.6%25.6%
Operating margin14.5%13.3%18.4%13.0%12.9%10.5%7.8%7.0%7.2%9.3%
Net margin6.9%7.2%12.0%6.9%6.5%5.5%3.5%2.6%2.8%5.0%
Free cash flow margin6.0%7.0%6.1%8.2%——————
Rule of 40 (growth + FCF margin)13.3%14.3%−0.9%13.9%——————
Return on capital—10.3%14.0%9.0%8.4%7.2%5.1%4.4%4.6%7.0%
Return on equity—12.9%18.4%10.1%10.1%8.1%5.0%3.6%3.8%7.0%
Return on assets—5.2%7.9%4.0%3.6%2.9%1.9%1.4%1.6%3.0%
Net debt to EBITDA4.3x2.1x1.4x2.1x1.8x2.1x2.2x2.2x1.9x1.7x
EUR millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, EUR millions)
Source: Fresenius Medical Care's Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Fresenius Medical Care.